318 related articles for article (PubMed ID: 35858407)
1. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
[TBL] [Abstract][Full Text] [Related]
2. SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein.
Walter M; Chen IP; Vallejo-Gracia A; Kim IJ; Bielska O; Lam VL; Hayashi JM; Cruz A; Shah S; Soveg FW; Gross JD; Krogan NJ; Jerome KR; Schilling B; Ott M; Verdin E
PLoS Pathog; 2022 Sep; 18(9):e1010811. PubMed ID: 36095012
[TBL] [Abstract][Full Text] [Related]
3. Cellular host factors for SARS-CoV-2 infection.
Baggen J; Vanstreels E; Jansen S; Daelemans D
Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
[TBL] [Abstract][Full Text] [Related]
4. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
Narayanan N; Nair DT
Int J Biol Macromol; 2021 Jan; 168():272-278. PubMed ID: 33309661
[TBL] [Abstract][Full Text] [Related]
5. Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2.
Shahid M; Shahzad-Ul-Hussan S
J Struct Biol; 2021 Mar; 213(1):107690. PubMed ID: 33383190
[TBL] [Abstract][Full Text] [Related]
6. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
Pearson LA; Green CJ; Lin D; Petit AP; Gray DW; Cowling VH; Fordyce EAF
SLAS Discov; 2021 Jul; 26(6):749-756. PubMed ID: 33724070
[TBL] [Abstract][Full Text] [Related]
7. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2.
Saramago M; Bárria C; Costa VG; Souza CS; Viegas SC; Domingues S; Lousa D; Soares CM; Arraiano CM; Matos RG
FEBS J; 2021 Sep; 288(17):5130-5147. PubMed ID: 33705595
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target.
Tahir M
J Med Virol; 2021 Jul; 93(7):4258-4264. PubMed ID: 33837972
[TBL] [Abstract][Full Text] [Related]
9. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.
Scholle MD; Liu C; Deval J; Gurard-Levin ZA
SLAS Discov; 2021 Jul; 26(6):766-774. PubMed ID: 33870746
[TBL] [Abstract][Full Text] [Related]
10. Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors.
Riccio AA; Sullivan ED; Copeland WC
J Biol Chem; 2022 Jan; 298(1):101518. PubMed ID: 34942146
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-host proteome interactions for antiviral drug discovery.
Liu X; Huuskonen S; Laitinen T; Redchuk T; Bogacheva M; Salokas K; Pöhner I; Öhman T; Tonduru AK; Hassinen A; Gawriyski L; Keskitalo S; Vartiainen MK; Pietiäinen V; Poso A; Varjosalo M
Mol Syst Biol; 2021 Nov; 17(11):e10396. PubMed ID: 34709727
[TBL] [Abstract][Full Text] [Related]
13. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
[TBL] [Abstract][Full Text] [Related]
14. Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.
Rajarshi K; Khan R; Singh MK; Ranjan T; Ray S; Ray S
Gene; 2021 Feb; 768():145313. PubMed ID: 33220345
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 virus NSP14 Impairs NRF2/HMOX1 activation by targeting Sirtuin 1.
Zhang S; Wang J; Wang L; Aliyari S; Cheng G
Cell Mol Immunol; 2022 Aug; 19(8):872-882. PubMed ID: 35732914
[TBL] [Abstract][Full Text] [Related]
16. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
17. Genome-scale CRISPR screens identify host factors that promote human coronavirus infection.
Grodzki M; Bluhm AP; Schaefer M; Tagmount A; Russo M; Sobh A; Rafiee R; Vulpe CD; Karst SM; Norris MH
Genome Med; 2022 Jan; 14(1):10. PubMed ID: 35086559
[TBL] [Abstract][Full Text] [Related]
18. Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.
Bhatt AN; Kumar A; Rai Y; Kumari N; Vedagiri D; Harshan KH; Chinnadurai V; Chandna S
Life Sci; 2022 Apr; 295():120411. PubMed ID: 35181310
[TBL] [Abstract][Full Text] [Related]
19. Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target.
Renz A; Widerspick L; Dräger A
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073716
[TBL] [Abstract][Full Text] [Related]
20. The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target.
Rona G; Zeke A; Miwatani-Minter B; de Vries M; Kaur R; Schinlever A; Garcia SF; Goldberg HV; Wang H; Hinds TR; Bailly F; Zheng N; Cotelle P; Desmaële D; Landau NR; Dittmann M; Pagano M
Cell Death Differ; 2022 Feb; 29(2):285-292. PubMed ID: 34862481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
